[gpt3]Summarize this content to 100 words:
April 11, 2025
2 min read
Key takeaways:
- Researchers did not find evidence that treatment gains from dual-focus myopia control contact lenses were lost after treatment ceased.
- Myopia progression at year 7 was greater in younger patients.
Regardless of duration of treatment, children who stopped wearing dual-focus contact lenses for myopia control maintained prior treatment gains, with eye growth rates similar to those of untreated myopic eyes, according to a study.
“These study results represent the culmination of over a decade of hard work and dedication by many individuals within CooperVision, as well as by everyone who partnered with us in conducting a clinical trial of this magnitude and duration,” study author Paul Chamberlain, MCOptom, senior director of research programs at CooperVision, told Healio.
Regardless of duration of treatment, children who stopped wearing dual-focus contact lenses for myopia control maintained prior treatment gains, according to a study published in Optometry and Vision Science. Image: Adobe Stock
The study was published in Optometry and Vision Science.
In previous studies, researchers have observed accelerated eye growth and myopia progression after patients ceased myopia control treatment, limiting the success of these interventions in the long term, Chamberlain and colleagues wrote, which prompted them to conduct a bilateral open-label trial to evaluate eye growth and refractive changes in patients with myopia after ceasing prolonged treatment with dual-focus contact lenses.
This study is part three of a larger trial in which Healio previously reported that dual-focus myopia control with the MiSight 1 day contact lens (CooperVision) slowed eye growth and myopia progression in children. The children received treatment for either 3 years (T3 group) or 6 years (T6 group) before proceeding to part three of the study.
In the current part three analysis, 83 participants (T3, n = 40; mean age, 16.1 years; 50% boys; T6, n = 43; mean age, 16.3 years; 51.2% boys) stopped myopia control treatment and were refit into single-vision Proclear 1 day contact lenses (omafilcon A, CooperVision). Thirty-nine participants in the T3 group and 37 participants in the T6 group attended the final follow-up 1 year later (year 7 of the total study).
The researchers measured axial length and cyclopleged spherical equivalent refractive error annually through the full length of the study.
During year 7, average myopia progression increased by 0.19 D (95% CI, 0.1798 to 0.1975) in the T3 group and 0.087 D (95% CI, 0.076 to 0.0974) in the T6 group. Average uncorrected axial growth increased by 0.022 mm (95% CI, 0.0196-0.0249) in the T3 group and 0.016 mm (95% CI, 0.0136-0.0183) in the T6 group.
According to a linear mixed model adjusted for age, sex and ethnicity, length of prior treatment with the MiSight 1 day dual-focus contact lens (3 years vs. 6 years) did not influence myopia progression after treatment ceased.
Further, using a model that assumed 15% axial growth slowing per year based on the mean axial growth of untreated eyes from the T3 group during year 3, the researchers estimated the average growth during year 7 would be 0.08 ± 0.05 mm had these eyes remained untreated. Comparatively, the observed average axial growth rates for the T3 (0.09 ± 0.09 mm) and T6 (0.1 ± 0.1 mm) groups were not significantly greater. A similar observation was made regarding myopia progression using a model with an estimated 10% slowing of myopia progression per year.
Children aged 8 to 10 years at baseline compared with children aged 11 to 12 years old at baseline experienced greater axial growth (0.13 ± 0.1 mm vs. 0.05 ± 0.07 mm) and myopia progression (0.26 ± 0.36 D vs. 0.17 ± 0.4 D) at year 7.
“We believed it was crucial to assess [eye growth and myopia progression] following 6 years of treatment, as it better reflects the real-world scenarios faced by eye care professionals when managing their patients,” Chamberlain told Healio. “The results, which show a return to age-expected growth rates, are encouraging news for eye care professionals, indicating that the treatment gains will be maintained even after the treatment is stopped.”
For more information:
Paul Chamberlain, MCOptom, can be reached at optometry@healio.com.
Sources/Disclosures
Collapse
Disclosures:
Chamberlain reports being an employee of CooperVision. Please see the study for all other authors’ relevant financial disclosures.
[/gpt
Source link